| 72.13 -0.05 (-0.07%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 84.58 | 1-year : | 98.79 |
| Resists | First : | 72.41 | Second : | 84.58 |
| Pivot price | 71.85  |
|||
| Supports | First : | 71.18 | Second : | 70.41 |
| MAs | MA(5) : | 72.19  |
MA(20) : | 71.77 |
| MA(100) : | 56.72 |
MA(250) : | 0 | |
| MACD | MACD : | 1.1 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 78.5 |
D(3) : | 81.4 |
| RSI | RSI(14): 72.8 |
|||
| 52-week | High : | 72.41 | Low : | 21.51 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RNA ] has closed below upper band by 29.7%. Bollinger Bands are 88.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 72.26 - 72.61 | 72.61 - 72.96 |
| Low: | 70.98 - 71.43 | 71.43 - 71.88 |
| Close: | 71.3 - 72.01 | 72.01 - 72.71 |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Thu, 18 Dec 2025
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week High - Here's Why - MarketBeat
Thu, 18 Dec 2025
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Sat, 13 Dec 2025
EcoR1 Capital LLC Sells 57,576 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Wed, 10 Dec 2025
Assessing Avidity Biosciences (RNA) Valuation After a 130% Year-to-Date Share Price Surge - Yahoo Finance
Thu, 04 Dec 2025
Avidity Biosciences, Inc. (RNA): A Bull Case Theory - Yahoo Finance
Mon, 10 Nov 2025
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 151 (M) |
| Held by Insiders | 1.2873e+008 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 10,500 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.0906e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 513.4 % |
| Return on Equity (ttm) | -20.3 % |
| Qtrly Rev. Growth | 2.087e+007 % |
| Gross Profit (p.s.) | 482.22 |
| Sales Per Share | -36.05 |
| EBITDA (p.s.) | -5.19244e+008 |
| Qtrly Earnings Growth | -4.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -581 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -2.01 |
| Price to Cash Flow | 5.05 |
| Dividend | 0 |
| Forward Dividend | 8.87e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|